The Annexure

News to 9 October 2026 ·

Desk›Healthcare› Pfizer Ltd

Pfizer Ltd

BSE 500680 · NSE PFIZER · ISIN INE182A01018 · Group A · Active

Healthcare › Healthcare › Pharmaceuticals & Biotechnology › Pharmaceuticals

₹4,743.95

-1.13%

BSE close, 28 August 2026

Market cap

₹21,702.50 cr

4.6 cr shares · Mid cap

Free float

₹7,171.57 cr

as published

P/E · P/B

29.5× · 5.79×

EPS ₹160.70 · BV ₹819.34

FY25-26 rev / PAT

2,519.65 / 722.43

₹ cr, as filed

Filings, window

12

3 selected · 25%

Regime

Reg 30

Sch. III Part A

Price 52-week, BSE

52-WK LOW ₹4,361.00 52-WK HIGH ₹5,561.55 ₹4,743.95 32% of range
Against 52-week high-14.7%
Against 52-week low+8.8%
Day change-1.13%
Size bandMid cap
Index membershipNIFTY 500

Valuation as published by BSE

Earnings per share₹160.70
Price / earnings29.52×
Price / book5.79×
Book value — derived, price ÷ P/B₹819.34
Return on equity19.60%
Operating margin44.77%
Net margin31.30%

Consistency check

P/B ÷ P/E, which must equal ROE
19.61%
ROE as published
19.60%

Results ₹ crore, as filed

RevenueNet profit one scale across all three periods, ₹ crore

PeriodRevenue ₹cr Net profit ₹cr EPS ₹OPM NPM
Jun-26 · Q 653.17 204.47 44.69 44.77% 31.30%
Mar-26 · Q 629.23 199.82 43.68 45.41% 31.76%
FY25-26 2,519.65 722.43 157.92 41.39% 28.67%

Quarter on quarter

Revenue, quarter on quarter
+3.8%
Net profit, quarter on quarter
+2.3%
Operating margin, quarter on quarter
-64 bps

Disclosure profile 12 filings in the window

0 median 17.0 p75 · 25 sector max 52 12 29th percentile of 300 Healthcare filers
Shaded is the middle half of the sector, 12 to 25 filings. Measured against the 300 Healthcare companies that filed at all in this window — companies with no filings are excluded, so this is a percentile against filers rather than against the sector.
TagFilings
Selected
Board Outcome1
Change in Directorate1
Change in Management1
Selected sub-total3
Procedural
AGM / EGM2
Newspaper Publication2
Board Meeting1
Compliance Certificate1
General1
Outcome1
Trading Window1
Procedural sub-total9
Total12

Disclosure regime

LODR Reg 30

Read with Schedule III Part A. An equity filer in BSE Group A, so the Regulation 30 disclosure framework and the Schedule III event list both apply.

Sources Price, day change, 52-week range — bse.quote, bse.quoteWeeklyHL, 28 August 2026 close. Market cap and free float — bse.getScripTradingStats. P/E, P/B, EPS, ROE, margins — bse.equityMetaInfo. Quarterly and annual results — bse.resultsSnapshot, standalone, as filed. Four-tier classification — data/reference/companies.csv. Filing counts and tags — the build aggregate for this window. Notes Book value is derived as price ÷ P/B; BSE does not publish it directly. Share count is derived as market cap ÷ price. Figures move between captures and between vendors, and the two are not an error in either: companies.csv carries the market cap from an earlier sweep than the snapshot above. EPS appears twice with different meanings — the figure beside P/E is the trailing one from equityMetaInfo, while the EPS in the results table is the per-period figure as filed.

Filing rhythm · 93 trading days

12 filings · 3 selected · busiest 2026-07-28 and 2026-09-29

Filing rhythm · the twelve most recent

2026-07-202026-10-09

SelectedProcedural

Filings

12 in the window · 10 earlier on record

  1. 9 October 2026 ·

    Compliance Certificate

    Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

    Please find attached Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended September 30, 2026.

    Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 View filing →

  2. 2 October 2026 ·

    Newspaper Publication

    Newspaper Publication

    Please find enclosed copy of newspaper advertisements for Transfer and Dematerialisation of Physical Securities.

    Company Update / Newspaper Publication View filing →

  3. 29 September 2026 ·

    Trading Window

    Closure of Trading Window

    Intimation for Closure of Trading Window.

    Insider Trading / SAST / Closure of Trading Window View filing →

  4. 29 September 2026 ·

    General

    Intimation Pursuant To Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015.

    Intimation for order issued by the Deputy/Additional Commissioner of Inc ome Tax Transfer Pricing.

    Company Update / General View filing →

  5. 18 September 2026 ·

    Change in Management

    Change in Management

    Intimation regarding change in Senior Management Personnel of the Company.

    Company Update / Change in Management View filing →

  6. 7 September 2026 ·

    Outcome

    Board Meeting Outcome for Discontinuation Of Minipress XL.

    Please find enclosed outcome of the Board Meeting held today i.e., September 7, 2026.

    Others / Outcome without intimation View filing →

  7. 4 August 2026 ·

    Newspaper Publication

    Newspaper Publication

    Newspaper Advertisement - Special Window for Re- lodgement of Transfer and Dematerialisation of Physical Securities.

    Company Update / Newspaper Publication View filing →

  8. 29 July 2026 ·

    AGM / EGM

    Shareholder Meeting / Postal Ballot-Scrutinizer's Report

    Pursuant to Regulation 44 of the SEBI (Listing Obligation and Disclosure Requirements) Regulation 2015, we submit herewith the consolidated Scrutinizer's Report of the votes cast through ....

    AGM/EGM / AGM View filing →

  9. 28 July 2026 ·

    AGM / EGM

    Shareholder Meeting / Postal Ballot-Outcome of AGM

    Pursuant to Regulation 30 of SEBI LODR Regulations, 2015, please find enclosed proceedings of the 75th Annual General Meeting of the Company held on July 28, 2026.

    AGM/EGM / AGM View filing →

  10. 28 July 2026 ·

    Board Outcome

    Board Meeting Outcome for Outcome Of Board Meeting - Unaudited Financial Results For The Quarter Ended June 30, 2026.

    Pursuant to Regulations 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we submit herewith the Unaudited Financial Results of the Company for ....

    Board Meeting / Outcome of Board Meeting View filing →

  11. 27 July 2026 ·

    Change in Directorate

    Change in Directorate

    Intimation of Resignation of Mr. Amit Agarwal, Executive Director -Finance & Chief Financial Officer

    Company Update / Change in Directorate View filing →

  12. 20 July 2026 ·

    Board Meeting

    Board Meeting Intimation for Board Meeting To Consider And Approve The Unaudited Financial Results For The Quarter Ended June 30, 2026.

    Pfizer Ltd has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 28/07/2026 ,inter alia, to consider and approve This is to inform that a meeting of ....

    Board Meeting / Board Meeting View filing →

RSS feed for Pfizer Ltd · the 50 most recent filings